CNS Pharmaceuticals, Inc. (CNSP) Stock Forecast
CNSP analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 1 analysts
- Price target
- $10.00 average of analyst targets
- Upside to target
- +106.1% from the latest close
- Next earnings
- November 13, 2026
- 52-week range
- $2.13 – $9.15
CNSP analyst ratings
1 analystsNumber of analysts at each rating.
CNSP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CNSP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.27 | −$0.27 | −$0.27 | −$5.76 | +95.3% | 1 |
| Current fiscal year (2026) | −$1.65 | −$1.65 | −$1.65 | −$35.75 | +95.4% | 1 |
| Next fiscal year (2027) | −$1.66 | −$1.66 | −$1.66 | −$1.65 | −0.6% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CNSP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
CNSP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CNSP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$0.74 | −$0.74 | −$0.74 | −$0.27 | — | 0 up · 0 down |
| Current fiscal year (2026) | −$6.33 | −$3.67 | −$3.67 | −$3.67 | −$1.65 | −73.9% | 1 up · 0 down |
| Next fiscal year (2027) | −$6.28 | −$2.89 | −$2.89 | −$2.89 | −$1.66 | −73.6% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CNSP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CNSP beat in 4 of 9.
What analysts expect from CNSP
1 analysts cover CNS Pharmaceuticals; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $10.00, 106.1% above the latest close of $4.85. Analysts expect earnings of −$1.65 per share for 2026, +95.4% from a year earlier. For 2027 the average estimate is −$1.66 per share. CNS Pharmaceuticals beat the EPS estimate in 4 of the last 9 quarters.
Related: CNSP income statement, CNSP key metrics, CNSP chart. See the CNSP stock overview for the latest quote and news.
CNSP forecast FAQ
What is CNS Pharmaceuticals's price target?
The average analyst price target for CNS Pharmaceuticals is $10.00, 106.1% above the latest close of $4.85.
Is CNS Pharmaceuticals a buy, hold or sell?
Of 1 analysts covering CNS Pharmaceuticals, 0 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is CNS Pharmaceuticals's EPS forecast?
Analysts forecast −$1.65 per share for 2026 (range −$1.65 to −$1.65); for 2027 the estimate is −$1.66.
When does CNS Pharmaceuticals report earnings?
CNS Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
Does CNS Pharmaceuticals usually beat earnings estimates?
CNS Pharmaceuticals reported EPS at or above the analyst estimate in 4 of the last 9 quarters.